Harvard Bioscience - HBIO Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1-year target prices for Harvard Bioscience's shares. Their HBIO share price forecasts range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price.
View analysts price targets for HBIO or view top-rated stocks among Wall Street analysts.

Harvard Bioscience's stock was trading at $2.77 at the start of the year. Since then, HBIO stock has increased by 6.9% and is now trading at $2.96.
View the best growth stocks for 2023 here.

Harvard Bioscience saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 265,600 shares, a decrease of 32.6% from the December 31st total of 394,100 shares. Based on an average trading volume of 137,800 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.7% of the shares of the stock are sold short.
View Harvard Bioscience's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our HBIO earnings forecast.

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings data on Tuesday, November, 8th. The medical instruments supplier reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by $0.05. The medical instruments supplier had revenue of $26.92 million for the quarter, compared to analyst estimates of $28 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 4.00% and a negative net margin of 5.84%.

Harvard Bioscience updated its fourth quarter 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.00 million-$30.00 million, compared to the consensus revenue estimate of $32.78 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Harvard Bioscience's stock is owned by many different retail and institutional investors. Top institutional investors include AMH Equity Ltd (5.41%) and Greenwood Capital Associates LLC (0.68%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HBIO stock can currently be purchased for approximately $2.96.

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $123.31 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

The company employs 475 workers across the globe.

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.